# reload+after+2024-01-21 18:46:01.416522
address1§450 East 29th Street
address2§14th Floor
city§New York
state§NY
zip§10016
country§United States
phone§646 860 7985
website§https://meiragtx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
fullTimeEmployees§407
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Alexandria  Forbes Ph.D.', 'age': 58, 'title': 'CEO, President & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 2332656, 'exercisedValue': 0, 'unexercisedValue': 416644}, {'maxAge': 1, 'name': 'Mr. Richard Brian Giroux B.A.', 'age': 50, 'title': 'COO & CFO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1829300, 'exercisedValue': 0, 'unexercisedValue': 385915}, {'maxAge': 1, 'name': 'Dr. Stuart  Naylor Ph.D.', 'age': 60, 'title': 'Chief Development Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1002860, 'exercisedValue': 0, 'unexercisedValue': 130054}, {'maxAge': 1, 'name': 'Mr. Robert J. Wollin J.D.', 'age': 47, 'title': 'General Counsel & Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michel  Michaelides M.D.', 'title': 'Head of Clinical Ophthalmology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine Elise Sheehy', 'age': 56, 'title': 'Senior Vice President of Global Integration', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tim  Randall', 'title': 'Senior Vice President of Risk & Internal Controls', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alastair  Leighton Ph.D.', 'title': 'Senior Vice President of Manufacturing & Supply Chain', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert K. Zeldin M.D.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1097400, 'exercisedValue': 0, 'unexercisedValue': 525000}]
auditRisk§3
boardRisk§3
compensationRisk§9
shareHolderRightsRisk§7
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.416
priceToSalesTrailing12Months§59.898693
currency§USD
dateShortInterest§1702598400
forwardEps§-1.46
pegRatio§-1.59
exchange§NMS
quoteType§EQUITY
shortName§MeiraGTx Holdings plc
longName§MeiraGTx Holdings plc
firstTradeDateEpochUtc§1528464600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§934d1a61-2bc1-31ce-acc9-153361189a8b
gmtOffSetMilliseconds§-18000000
targetHighPrice§36.0
targetLowPrice§11.0
targetMeanPrice§22.2
targetMedianPrice§20.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§1.508
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
